Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization

Ovarian cancer is one of the leading causes of cancer-related death among women. Resistance to the disease occurs in more than 70% of the cases even after treated with chemotherapy agents such as paclitaxel- and platinum-based agents. The immune system is increasingly becoming a target for intense r...

Full description

Saved in:
Bibliographic Details
Main Authors: Nikos G. Gavalas, Alexandra Karadimou, Meletios A. Dimopoulos, Aristotelis Bamias
Format: Article
Language:English
Published: Wiley 2010-01-01
Series:Clinical and Developmental Immunology
Online Access:http://dx.doi.org/10.1155/2010/791603
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832549823457263616
author Nikos G. Gavalas
Alexandra Karadimou
Meletios A. Dimopoulos
Aristotelis Bamias
author_facet Nikos G. Gavalas
Alexandra Karadimou
Meletios A. Dimopoulos
Aristotelis Bamias
author_sort Nikos G. Gavalas
collection DOAJ
description Ovarian cancer is one of the leading causes of cancer-related death among women. Resistance to the disease occurs in more than 70% of the cases even after treated with chemotherapy agents such as paclitaxel- and platinum-based agents. The immune system is increasingly becoming a target for intense research in order to study the host's immune response against ovarian cancer. T cell populations, including NK T cells and Tregs, and cytokines have been associated with disease outcome, indicating their increasing clinical significance, having been associated with prognosis and as markers of disease progress, respectively. Harnessing the immune system capacity in order to induce antitumor response remains a major challenge. This paper examines the recent developments in our understanding of the mechanisms of development of the immune response in ovarian cancer as well as its prognostic significance and the existing experience in clinical studies.
format Article
id doaj-art-caae8fbc89c04361b31f2d742bac7c22
institution Kabale University
issn 1740-2522
1740-2530
language English
publishDate 2010-01-01
publisher Wiley
record_format Article
series Clinical and Developmental Immunology
spelling doaj-art-caae8fbc89c04361b31f2d742bac7c222025-02-03T06:08:36ZengWileyClinical and Developmental Immunology1740-25221740-25302010-01-01201010.1155/2010/791603791603Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment UtilizationNikos G. Gavalas0Alexandra Karadimou1Meletios A. Dimopoulos2Aristotelis Bamias3Department of Clinical Therapeutics, Medical School, University of Athens, Alexandra Hospital, 80 Vasilissis Sofias Avenue, 115 28 Athens, GreeceDepartment of Clinical Therapeutics, Medical School, University of Athens, Alexandra Hospital, 80 Vasilissis Sofias Avenue, 115 28 Athens, GreeceDepartment of Clinical Therapeutics, Medical School, University of Athens, Alexandra Hospital, 80 Vasilissis Sofias Avenue, 115 28 Athens, GreeceDepartment of Clinical Therapeutics, Medical School, University of Athens, Alexandra Hospital, 80 Vasilissis Sofias Avenue, 115 28 Athens, GreeceOvarian cancer is one of the leading causes of cancer-related death among women. Resistance to the disease occurs in more than 70% of the cases even after treated with chemotherapy agents such as paclitaxel- and platinum-based agents. The immune system is increasingly becoming a target for intense research in order to study the host's immune response against ovarian cancer. T cell populations, including NK T cells and Tregs, and cytokines have been associated with disease outcome, indicating their increasing clinical significance, having been associated with prognosis and as markers of disease progress, respectively. Harnessing the immune system capacity in order to induce antitumor response remains a major challenge. This paper examines the recent developments in our understanding of the mechanisms of development of the immune response in ovarian cancer as well as its prognostic significance and the existing experience in clinical studies.http://dx.doi.org/10.1155/2010/791603
spellingShingle Nikos G. Gavalas
Alexandra Karadimou
Meletios A. Dimopoulos
Aristotelis Bamias
Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization
Clinical and Developmental Immunology
title Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization
title_full Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization
title_fullStr Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization
title_full_unstemmed Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization
title_short Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization
title_sort immune response in ovarian cancer how is the immune system involved in prognosis and therapy potential for treatment utilization
url http://dx.doi.org/10.1155/2010/791603
work_keys_str_mv AT nikosggavalas immuneresponseinovariancancerhowistheimmunesysteminvolvedinprognosisandtherapypotentialfortreatmentutilization
AT alexandrakaradimou immuneresponseinovariancancerhowistheimmunesysteminvolvedinprognosisandtherapypotentialfortreatmentutilization
AT meletiosadimopoulos immuneresponseinovariancancerhowistheimmunesysteminvolvedinprognosisandtherapypotentialfortreatmentutilization
AT aristotelisbamias immuneresponseinovariancancerhowistheimmunesysteminvolvedinprognosisandtherapypotentialfortreatmentutilization